Wen Jiang
Associate Professor
The University of Texas MD Anderson Cancer Center
Department of Radiation Oncology
The primary research focus of the Jiang lab is the development of novel therapeutic strategies to
re-program the immune suppressive tumor microenvironment to ultimately enhance cancer
immunotherapies. We are interested in identifying immune suppressive mechanisms intrinsic to
the tumor microenvironment and developing novel therapeutic approaches to neutralize or even
re-program the tumor microenvironment to promote immune-mediated tumor eradication. We
are also investigating novel strategies for combination therapy of conventional cancer treatment
and immunotherapy to achieve synergistic treatment effects. Another research focus of our lab
group is to design nanomedicine for cancer therapies. Our research philosophy integrates
bioengineering and tumor biology to characterize the complex interactions between intratumoral
immune cells and cancer cells in solid tumors, with a particular focus on immune checkpoint
inhibitors, in order to design better treatment strategies to enhance overall anti-tumor immunity.
This includes developing novel bispecific immuno-bioconjugates to promote tumor cell
phagocytosis as a new form of cancer immunotherapy.
Current projects in the lab include testing the treatment efficacy of novel drugs that may activate
anti-tumoral immune response and designing nanomedicine for cancer treatment. We utilize
molecular biology and cell culture methods to understand mechanisms of drug and immune
activation, including the use of mouse tumor models and targeted immune system adjuvants.
Education & Training
PhD, University of Toronto, 2008
MD, Stanford University, 2013